🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We received U.S. FDA approval for our new presentation of potassium phosphates in 0.9% sodium chloride injection intravenous (IV) ready-to-use (RTU) bags. For full prescribing information, see package insert: dailymed.nlm.nih.gov/dailymed/fda/f…

Amneal’s momentum is increasing across our portfolios. Please reference Amneal’s 2nd Quarter press release for more info, including non-GAAP financial measures, reconciliations & risks related to forward-looking statements:: investors.amneal.com/news/press-rel…

We received approval from the U.S. FDA for Propofol Injectable Emulsion USP, 200 mg/20 mL (10 mg/mL), 500 mg/50 mL (10 mg/mL), and 1,000 mg/100 mL (10 mg/mL), Single-Dose Vials. See Press Release for additional product information. investors.amneal.com/news/press-rel…

This International Overdose Awareness Day, we are announcing the launch of #TakingControlOverIt, a movement that aims to raise awareness about the opioid crisis and how you can be prepared to act in the event of an overdose. Learn more: TakingControlOverIt.com

Amneal and Shilpa announced U.S. FDA approval for BORUZU™, a new ready-to-use (RTU) presentation of bortezomib for subcutaneous administration or may be further diluted for intravenous (IV) administration. For full prescribing info, see package insert: amneal.com/wp-content/upl…

We are thrilled to be collaborating with Metsera to enable the efficient development and large-scale supply of a portfolio of new weight loss medicines globally. Read more: investors.amneal.com/news/press-rel…

We are proud to announce the launch of RANIVUE™, Amneal’s first Ranibizumab biosimilar in India. This milestone expands our ophthalmology portfolio and patient access to high-quality, innovative medicines in India.

We are building Amneal as a leading, diversified global pharmaceutical company. Please reference Amneal’s 3rd Quarter press release for more info, including non-GAAP financial measures, reconciliations and risks related to forward-looking statements: investors.amneal.com/news/press-rel…

Today we announced advancements to our specialty and complex generic development pipelines. investors.amneal.com/news/press-rel…

Today we announced three generic product advancements in our Affordable Medicines business. Learn more: investors.amneal.com/news/press-rel…

We announced two complex product advancements in our Affordable Medicines portfolio. Learn more: investors.amneal.com/news/press-rel…

Today we announced strong 4th Quarter and Full Year 2024 financial results. For more info, including non-GAAP financial measures, reconciliations and risks related to forward-looking statements: investors.amneal.com/news/press-rel…

We are building our position in the U.S. biosimilars market as this next wave of affordable medicines increases access for patients to biologics. Learn more: investors.amneal.com/news/press-rel…

We announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. investors.amneal.com/news/press-rel… For full prescribing information, see here: cts.businesswire.com/ct/CT?id=smart…

Parkinson’s patients face numerous daily challenges, and we believe that access to medication should not be one of them. We are committed to continuing our research, support and education for this resilient community that we have come to know and care for. investors.amneal.com/news/press-rel…

We continue to expand the body of research supporting CREXONT®, carbidopa and levodopa (CD/LD) extended-release capsules, and its positive impact on Parkinson’s disease patients. investors.amneal.com/news/press-rel… See Indication and Prescribing Info on: bit.ly/3WKqSHy

Today we announced strong 1st Quarter financial results. For more info, including non-GAAP financial measures, reconciliations and risks related to forward-looking statements: investors.amneal.com/news/press-rel…

We announced a new strategic collaboration with Apiject to expand domestic production of sterile injectable drug dosage forms, including prefilled injectables, ophthalmics and inhalation, at Amneal’s Brookhaven, NY facility. globenewswire.com/news-release/2…

We’re excited about our collaboration with Apiject; and the opportunity to expand our Made-in-America manufacturing footprint with advanced sterile pharmaceutical capabilities.

Brekiya® (dihydroergotamine mesylate) injection is approved by the U.S. FDA: investors.amneal.com/news/press-rel… See full Prescribing Information, including BOXED WARNING at Brekiya.com.